PMID- 25356804
OWN - NLM
STAT- MEDLINE
DCOM- 20150320
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 112
IP  - 2
DP  - 2015 Jan 20
TI  - Influence of segmental chromosome abnormalities on survival in children over the 
      age of 12 months with unresectable localised peripheral neuroblastic tumours 
      without MYCN amplification.
PG  - 290-5
LID - 10.1038/bjc.2014.557 [doi]
AB  - BACKGROUND: The prognostic impact of segmental chromosome alterations (SCAs) in 
      children older than 1 year, diagnosed with localised unresectable neuroblastoma 
      (NB) without MYCN amplification enrolled in the European Unresectable 
      Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of 
      patients, the presence of SCAs is associated with poor prognosis. METHODS: To 
      understand the role of SCAs we performed multilocus/pangenomic analysis of 98 
      tumour samples from patients enrolled in the EUNB protocol. RESULTS: Age at 
      diagnosis was categorised into two groups using 18 months as the age cutoff. 
      Significant difference in the presence of SCAs was seen in tumours of patients 
      between 12 and 18 months and over 18 months of age at diagnosis, respectively 
      (P=0.04). A significant correlation (P=0.03) was observed between number of SCAs 
      per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in 
      both age groups, according to both the presence and number of SCAs. In older 
      patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 
      75%, P=0.023; OS=66.8% vs 100%, P=0.003). Moreover, OS of older patients 
      inversely correlated with number of SCAs (P=0.002). Finally, SCAs provided 
      additional prognostic information beyond histoprognosis, as their presence was 
      associated with poorer OS in patients over 18 months with unfavourable 
      International Neuroblastoma Pathology Classification (INPC) histopathology 
      (P=0.018). CONCLUSIONS: The presence of SCAs is a negative prognostic marker that 
      impairs outcome of patients over the age of 18 months with localised unresectable 
      NB without MYCN amplification, especially when more than one SCA is present. 
      Moreover, in older patients with unfavourable INPC tumour histoprognosis, the 
      presence of SCAs significantly affects OS.
FAU - Defferrari, R
AU  - Defferrari R
AD  - Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
FAU - Mazzocco, K
AU  - Mazzocco K
AD  - Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
FAU - Ambros, I M
AU  - Ambros IM
AD  - Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna 1090, 
      Austria.
FAU - Ambros, P F
AU  - Ambros PF
AD  - Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna 1090, 
      Austria.
FAU - Bedwell, C
AU  - Bedwell C
AD  - Northern Genetics Service, Newcastle upon Tyne NEI 3 BZ, UK.
FAU - Beiske, K
AU  - Beiske K
AD  - Department of Pathology, Oslo University Hospital Rikshopitalet, Oslo 0424, 
      Norway.
FAU - Benard, J
AU  - Benard J
AD  - Departement de Biologie et de Pathologie Medicales, Gustave Roussy Cancer Campus, 
      Villejuif 94800, France.
FAU - Berbegall, A P
AU  - Berbegall AP
AD  - Department of Pathology, Medical School of Valencia, University of Valencia, 
      Valencia 46010, Spain.
FAU - Bown, N
AU  - Bown N
AD  - Northern Genetics Service, Newcastle upon Tyne NEI 3 BZ, UK.
FAU - Combaret, V
AU  - Combaret V
AD  - Laboratoire de Recherche Translationnelle, Centre Leon-Berard, Lyon 69008, 
      France.
FAU - Couturier, J
AU  - Couturier J
AD  - Unite de Genetique Somatique et Cytogenetique, Institut Curie, Paris Cedex 05 
      75248, France.
FAU - Erminio, G
AU  - Erminio G
AD  - Epidemiology, Biostatistics and Committees Unit, Istituto Giannina Gaslini, 
      Genova 16148, Italy.
FAU - Gambini, C
AU  - Gambini C
AD  - Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
FAU - Garaventa, A
AU  - Garaventa A
AD  - Department of Haematology-Oncology, Istituto Giannina Gaslini, Genova 16148, 
      Italy.
FAU - Gross, N
AU  - Gross N
AD  - Pediatric Oncology Research Unit, Lausanne University Hospital (CHUV), Lausanne 
      1011, Switzerland.
FAU - Haupt, R
AU  - Haupt R
AD  - Epidemiology, Biostatistics and Committees Unit, Istituto Giannina Gaslini, 
      Genova 16148, Italy.
FAU - Kohler, J
AU  - Kohler J
AD  - Department of Paediatric Oncology, Southampton General Hospital, Southampton S016 
      6YD, UK.
FAU - Jeison, M
AU  - Jeison M
AD  - Cancer Cytogenetique and Molecular Cytogenetique Laboratory, Schneider Children's 
      Medical Center of Israel, Petah Tikva, Israel.
FAU - Lunec, J
AU  - Lunec J
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle NE2 4HH, 
      UK.
FAU - Marques, B
AU  - Marques B
AD  - Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, 
      Lisbon 1649-016, Portugal.
FAU - Martinsson, T
AU  - Martinsson T
AD  - Department of Clinical Genetics, Goteborg University, Sahlgrenska University 
      Hospital, Goteborg 413 45, Sweden.
FAU - Noguera, R
AU  - Noguera R
AD  - Department of Pathology, Medical School of Valencia, University of Valencia, 
      Valencia 46010, Spain.
FAU - Parodi, S
AU  - Parodi S
AD  - Institute of Electronics, Computer and Telecommunication Engineering, National 
      Research Council, Genova 16149, Italy.
FAU - Schleiermacher, G
AU  - Schleiermacher G
AD  - 1] INSERM U830, Laboratoire de Genetique et Biologie des Cancers, Paris Cedex 05 
      75248, France [2] Departement d'Oncologie Pediatrique, Institut Curie, Paris 
      Cedex 05 75248, France.
FAU - Tweddle, D A
AU  - Tweddle DA
AD  - Northern Institute for Cancer Research, Newcastle University, Newcastle NE2 4HH, 
      UK.
FAU - Valent, A
AU  - Valent A
AD  - Departement de Biologie et de Pathologie Medicales, Gustave Roussy Cancer Campus, 
      Villejuif 94800, France.
FAU - Van Roy, N
AU  - Van Roy N
AD  - Center for Medical Genetics, Ghent University Hospital, Ghent 9000, Belgium.
FAU - Vicha, A
AU  - Vicha A
AD  - Department of Paediatric Haematology and Oncology, Charles University and 
      University Hospital Motol, Prague 15008, Czech Republic.
FAU - Villamon, E
AU  - Villamon E
AD  - Department of Hematology, Hospital Universitari i Politecnic La Fe, Valencia 
      46009, Spain.
FAU - Tonini, G P
AU  - Tonini GP
AD  - Laboratory of Neuroblastoma, Onco/Haematology Laboratory, University of Padua, 
      Pediatric Research Institute (IRP)-Citta della Speranza, Corso Stati Uniti 4, 
      Padova 35127, Italy.
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141104
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins)
SB  - IM
MH  - Chromosome Aberrations
MH  - Comparative Genomic Hybridization
MH  - Disease-Free Survival
MH  - Gene Amplification
MH  - Humans
MH  - Infant
MH  - Kaplan-Meier Estimate
MH  - N-Myc Proto-Oncogene Protein
MH  - Neuroblastoma/diagnosis/*genetics/mortality
MH  - Nuclear Proteins/genetics
MH  - Oncogene Proteins/genetics
MH  - Peripheral Nervous System Neoplasms/diagnosis/*genetics/mortality
MH  - Prognosis
PMC - PMC4453444
EDAT- 2014/10/31 06:00
MHDA- 2015/03/21 06:00
PMCR- 2016/01/20
CRDT- 2014/10/31 06:00
PHST- 2014/05/26 00:00 [received]
PHST- 2014/09/22 00:00 [revised]
PHST- 2014/10/04 00:00 [accepted]
PHST- 2014/10/31 06:00 [entrez]
PHST- 2014/10/31 06:00 [pubmed]
PHST- 2015/03/21 06:00 [medline]
PHST- 2016/01/20 00:00 [pmc-release]
AID - bjc2014557 [pii]
AID - 10.1038/bjc.2014.557 [doi]
PST - ppublish
SO  - Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 
      4.